Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 20681032

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Cancer
Publication date
2010 Dec 1
First author
Slomovitz BM

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Slomovitz BM
      type
      Author
    2. name
      Lu KH
      type
      Author
    3. name
      Johnston T
      type
      Author
    4. name
      Coleman RL
      type
      Author
    5. name
      Munsell M
      type
      Author
    6. name
      Broaddus RR
      type
      Author
    7. name
      Walker C
      type
      Author
    8. name
      Ramondetta LM
      type
      Author
    9. name
      Burke TW
      type
      Author
    10. name
      Gershenson DM
      type
      Author
    11. name
      Wolf J
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Slomovitz BM
      type
      Author
    2. name
      Lu KH
      type
      Author
    3. name
      Johnston T
      type
      Author
    4. name
      Coleman RL
      type
      Author
    5. name
      Munsell M
      type
      Author
    6. name
      Broaddus RR
      type
      Author
    7. name
      Walker C
      type
      Author
    8. name
      Ramondetta LM
      type
      Author
    9. name
      Burke TW
      type
      Author
    10. name
      Gershenson DM
      type
      Author
    11. name
      Wolf J
      type
      Author
    bibliography ids
    1. nci-bib-95dc950ff70a42bf13f3e13c
    book metadata
    content sha256
    2f62d48b45412a42fc29a53698201d198ddb4d449faec0b5ed8a20743c459e9d
    document type
    citation
    dois
    1. 10.1002/cncr.25515
    electronic publication date
    display
    2010 Aug 2
    precision
    day
    year
    2010
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:20681032
    immutable id
    pubmed:20681032@2f62d48b45412a42fc29a53698201d198ddb4d449faec0b5ed8a20743c459e9d
    journal
    abbreviation
    Cancer
    issn electronic
    1097-0142
    issn print
    0008-543X
    issue
    23
    name
    Cancer
    nlm unique id
    0374236
    pages
    5415-9
    volume
    116
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      20681032
      provenance
      batch id
      10a38257e12e9ed1867a
      provider
      NCBI PubMed ESummary
      record sha256
      cbc2e653e04641cc0fb37b8478a91683e3525fd30125d4f04407e2ebea880c87
      response sha256
      84c4808ca38b35d999cfdf809eb088835175ab38d71586c626096d677096bbcc
      retrieved at
      2026-09-09T23:46:35.793530+00:00
      publication date
      display
      2010 Dec 1
      precision
      day
      year
      2010
      publication types
      1. Clinical Trial, Phase II
      2. Journal Article
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/20681032/
      title
      A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.

      Preserved source evidence · Not medical advice